Relevant bibliographies by topics / Rheumatoid arthritis Prognosis

Academic literature on the topic 'Rheumatoid arthritis Prognosis'

Author: Grafiati
Published: 10 December 2022
Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Rheumatoid arthritis Prognosis.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Rheumatoid arthritis Prognosis"

1

Weisman, Michael H. "Prognosis in rheumatoid arthritis." Current Opinion in Rheumatology 2, no. 3 (June 1990): 458–62. http://dx.doi.org/10.1097/00002281-199002030-00008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ciofoaia, Elena I., Anjani Pillarisetty, and Florina Constantinescu. "Health disparities in rheumatoid arthritis." Therapeutic Advances in Musculoskeletal Disease 14 (January 2022): 1759720X2211371. http://dx.doi.org/10.1177/1759720x221137127.

Full text
Abstract:
Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation that involves symmetric polyarthritis of small and large joints. Autoimmune rheumatic diseases represent a significant socioeconomic burden as they are among the leading causes of death and morbidity due to increased risk of cardiovascular disease. Health disparities in patients with rheumatoid arthritis affect outcomes, prognosis, and management of the disease.
APA, Harvard, Vancouver, ISO, and other styles
3

Dariushnejad, Hassan, Leila Chodari, Mehrnoosh Sedighi, Soheila Akbari, and Vajihe Ghorbanzadeh. "Rheumatoid arthritis: current therapeutics compendium." Endocrine Regulations 56, no. 2 (April 1, 2022): 148–62. http://dx.doi.org/10.2478/enr-2022-0016.

Full text
Abstract:
Abstract Rheumatoid arthritis is a common chronic inflammatory disease with substantial economic, social, and personal costs. Its pathogenesis is multifactorial and complex. The ultimate goal of rheumatoid arthritis treatment is stopping or slowing down the disease progression. In the past two decades, invention of new medicines, especially biologic agents, revolutionized the management of this disease. These agents have been associated with an improved prognosis and clinical remission, especially in patients who did not respond to traditional disease-modifying anti-rheumatic drugs (DMARDs). Improvement in the understanding of the rheumatoid arthritis pathogenesis leads to the development of novel biologic therapeutic approaches. In the present paper, we summarized the current therapeutics, especially biologic agents, available for the treatment of rheumatoid arthritis.
APA, Harvard, Vancouver, ISO, and other styles
4

Kahan, A., and C.-J. Menkès. "The use of antimalarials in combination with other disease modifying agents in rheumatoid arthritis–the French Experience." Lupus 5, no. 1_suppl (June 1996): 45–49. http://dx.doi.org/10.1177/0961203396005001111.

Full text
Abstract:
A significant proportion of patients with rheumatoid arthritis have an aggressive, severe disease that may contribute to excess mortality. It has been suggested that early, aggressive therapy might improve the prognosis of these patients with active, severe rheumatoid arthritis. Combinations of disease modifying anti-rheumatic drugs including antimalarials are increasingly used in patients with active disease. While several open trials showed encouraging results, some controlled studies gave less support for the use of combination therapy. Ongoing controlled trials of double or triple combination therapy, such as hydroxychloroquine, methotrexate and sulphasalazine, should help define its place in treating patients with rheumatoid arthritis.
APA, Harvard, Vancouver, ISO, and other styles
5

Anghel, Daniela, Oana-Georgiana Petrache, Maria Laura Groșeanu, Maria Magdalena Negru, Cristina Florentina Pleșa, and Florentina Ioniţă Radu. "The Implication of Videocapillaroscopy in Rheumatoid Arthritis and Psoriatic Arthritis." Internal Medicine 19, no. 2 (February 1, 2022): 55–61. http://dx.doi.org/10.2478/inmed-2022-0207.

Full text
Abstract:
Abstract Videocapillaroscopy is an easy, noninvasive examination method that detects morphological microvascular abnormalities, such as nailfold capillaries. This method has a low cost, has high sensitivity and specificity, has reproductibility and the results can be easily interpreted. Besides its importance in the evaluation of Raynaud’s phenomenon and systemic sclerosis, nailfold capillaroscopy may play an important role in the diagnosis, evaluation and prognosis of other rheumatic diseases, such as rheumatoid arthritis and psoriatic arthritis. Because there are not enough data, currently, capillaroscopy is not routinely used in these patients. The aim of this review is to present the implications of the videocapillaroscopy in rheumatic diseases, other than systemic sclerosis, in order to promote this method as a routine investigation in rheumatic patients.
APA, Harvard, Vancouver, ISO, and other styles
6

Druce, Katie L., and Neil Basu. "Predictors of fatigue in rheumatoid arthritis." Rheumatology 58, Supplement_5 (November 1, 2019): v29—v34. http://dx.doi.org/10.1093/rheumatology/kez346.

Full text
Abstract:
Abstract People with RA commonly experience fatigue. Fatigue is a key contributor to increased clinical care costs, primary care consultations and employment loss. Despite this, our understanding of the prognostic of factors of poor fatigue outcomes is lacking and fatigue is poorly managed. Examining longitudinal predictors of fatigue can identify both individuals ‘at risk’ of poor prognosis, and candidate mechanisms that are worthy of greater inspection. This review discusses the factors most commonly investigated as being implicated in the prognosis of RA fatigue. The available data appears to implicate generic factors such as pain, mental health, disability and sleep as consistent predictors of fatigue outcome, while the role of disease activity and inflammation seems less clear. However, the existing data are not without methodological limitations and there have been no specific studies primarily designed to investigate the inflammatory biomarkers of fatigue. Future studies are required to more comprehensively and robustly determine the mechanisms of fatigue.
APA, Harvard, Vancouver, ISO, and other styles
7

Lu, Haifeng, Yujun Yao, Jiezuan Yang, Hua Zhang, and Lanjuan Li. "Microbiome–miRNA interactions in the progress from undifferentiated arthritis to rheumatoid arthritis: evidence, hypotheses, and opportunities." Rheumatology International 41, no. 9 (April 15, 2021): 1567–75. http://dx.doi.org/10.1007/s00296-021-04798-3.

Full text
Abstract:
AbstractThe human microbiome has attracted attention for its potential utility in precision medicine. Increasingly, more researchers are recognizing changes in intestinal microbiome can upset the balance between pro- and anti-inflammatory factors of host immune system, potentially contributing to arthritis immunopathogenesis. Patients who develop rheumatoid arthritis from undifferentiated arthritis can face multiple irreversible joint lesions and even deformities. Strategies for identifying undifferentiated arthritis patients who have a tendency to develop rheumatoid arthritis and interventions to prevent rheumatoid arthritis development are urgently needed. Intestinal microbiome dysbiosis and shifts in the miRNA profile affect undifferentiated arthritis progression, and may play an important role in rheumatoid arthritis pathophysiologic process via stimulating inflammatory cytokines and disturbing host and microbial metabolic functions. However, a causal relationship between microbiome–miRNA interactions and rheumatoid arthritis development from undifferentiated arthritis has not been uncovered yet. Changes in the intestinal microbiome and miRNA profiles of undifferentiated arthritis patients with different disease outcomes should be studied together to uncover the role of the intestinal microbiome in rheumatoid arthritis development and to identify potential prognostic indicators of rheumatoid arthritis in undifferentiated arthritis patients. Herein, we discuss the possibility of microbiome–miRNA interactions contributing to rheumatoid arthritis development and describe the gaps in knowledge regarding their influence on undifferentiated arthritis prognosis that should be addressed by future studies.
APA, Harvard, Vancouver, ISO, and other styles
8

Shlopak, Lev. "Diagnosis of rheumatoid arthritis." Spravočnik vrača obŝej praktiki (Journal of Family Medicine), no. 3 (March 1, 2020): 29–36. http://dx.doi.org/10.33920/med-10-2003-03.

Full text
Abstract:
Rheumatoid arthritis is a chronic systemic autoimmune disease of the connective tissue, accompanied by a primary lesion of peripheral joints with the development of erosive-destructive changes and ankylosis. It is one of the most common chronic inflammatory diseases in humans. Early diagnosis of this pathology contributes to the timely start of therapy, which allows to reduce the level of disability and improve the prognosis for this group of patients.
APA, Harvard, Vancouver, ISO, and other styles
9

Бестаев, D. Bestaev, Божьева, and L. Bozheva. "Clinical, laboratory and instrumental characteristics in patients with rheumatoid arthritis with "ground glass opacity" computed tomographic symptom of interstitial lung disease." Journal of New Medical Technologies. eJournal 9, no. 1 (April 17, 2015): 0. http://dx.doi.org/10.12737/10474.

Full text
Abstract:
Rheumatoid arthritis is an inflammatory rheumatic disease with unknown etiology characterized by symmetric, chronic and erosive arthritis (synovitis) of the peripheral joints and systemic inflammatory involvement of the viscera. Lung pathology, including interstitial lung disease, is one of the common extra-articular manifestations at the гheumatoid arthritis. The leading diagnosis method of interstitial lung disease is a computed tomography high resolution, which allows to identifying interstitial lung changes in 70% of the cases. The study of prognosis in patients with rheumatoid arthritis interstitial lung disease has been the subject of several studies in the past decade. In most studies it was stated that the average life expectancy from diagnosis is around 3 years. This work is devoted to study of interstitial lung disease as one of the most frequent extra-articular ma-nifestations of rheumatoid arthritis. The authors defined the significance of computed tomography high resolu-tion for the diagnosis of pulmonary interstitial lung changes at rheumatoid arthritis. They give comparative clini-cal and immunological, instrumental characteristics of rheumatoid arthritis patients with interstitial lung disease and without it. The role of smoking and positivity of anti-cyclic citrullinated peptide (anti-CCP) according to antibodies are determined as risk factors of interstitial lung disease development in patients with rheumatoid arthritis. The interrelation of the X-ray tomography symptom of interstitial lung disease "ground glass opacity" with the activity and duration of rheumatoid arthritis is revealed. "Ground glass opacity" symptom is associated with high index of DAS28 in patients with rheumatoid arthritis with interstitial lung disease.
APA, Harvard, Vancouver, ISO, and other styles
10

Dakin, Stephanie G. "Synovial signatures signpost arthritis." Science Translational Medicine 11, no. 488 (April 17, 2019): eaax1725. http://dx.doi.org/10.1126/scitranslmed.aax1725.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Rheumatoid arthritis Prognosis"

1

Sreerangaiah, Dee. "Qualification of ultrasonography as a biomarker of prognosis and response to treatment in early rheumatoid arthritis." Thesis, Imperial College London, 2012. http://hdl.handle.net/10044/1/24958.

Full text
Abstract:
Objectives: to assess the value of quantitative vascular imaging by power Doppler ultrasound (PDUS) as a tool that can be used to stratify patient risk of joint damage in early seropositive RA while still biologic-naive but on synthetic DMARD treatment. Methods: 85 patients with seropositive RA <3 years duration, had clinical, laboratory and imaging assessments at 0, 6 and 12 months. Imaging assessments consisted of radiographs of hands and feet, 2 dimensional high frequency and PDUS imaging of 10 metacarpophalangeal joints (MCPJs) which were scored for erosions and vascularity, and 3 dimensional PDUS of MCPJs and wrists which were scored for vascularity. Results: Severe deterioration on radiographs and ultrasonography was seen in 45% and 28% of patients respectively. 3D PD volume and 2D vascularity scores were the most useful ultrasound predictors of deterioration. These variables were modelled in 2 equations which estimate structural damage over 12 months. The equations had a sensitivity of 63.2% and specificity of 80.9% for predicting structural damage on x-ray, and a sensitivity of 54.2% and specificity of 96.7% for predicting structural damage on ultrasound. Conclusions: In seropositive early RA, quantitative vascular imaging by PDUS has clinical utility in predicting which patients would derive benefit from early use of biologics therapy.
APA, Harvard, Vancouver, ISO, and other styles
2

Manivel, Vivek Anand. "The role of anti-collagen type II antibodies in the pathogenesis and prognosis of rheumatoid arthritis." Doctoral thesis, Uppsala universitet, Klinisk immunologi, 2017. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-311959.

Full text
Abstract:
Rheumatoid arthritis (RA) which affects 0.5-1% of the world population and is characterised by joint erosions and presence of the autoantibodies anti-citrullinated protein antibodies (ACPA) and rheumatoid factor. Collagen II (CII) is a joint-specific antigen and we have shown that antibodies against CII (anti-CII) are present in around 8% of RA patients. RA patients with anti-CII are characterized by acute RA onset with elevated CRP and early joint erosions at the time of RA onset. Polymorphonuclear granulocytes (PMN) and peripheral blood mononuclear cells (PBMC) are abundant in RA synovial fluids, where they can interact with anti-CII, thus forming immune complexes (IC) with CII. In my thesis I have shown that PMN upregulated the cell surface markers CD66b and CD11b and downregulated CD16 and CD32 after stimulation with anti-CII IC. These changes in CD66b and CD16 associated to joint erosions to a larger extent than did PBMC responses to anti-CII IC. PMN cocultured with PBMC and stimulated with anti-CII IC showed augmented chemokine production that was dependent on TLR4 and functionally active PMN enzymes. This mechanism can lead to accumulation of inflammatory cells in joints of RA patients who are anti-CII positive around the time of RA diagnosis, and may thus help explain the acute onset RA phenotype associated with anti-CII. In a large Swedish RA cohort, anti-CII associated with elevations in clinical and laboratory measures of disease activity at diagnosis and until 6 months, whereas ACPA associated with late inflammation. Anti-CII seropositive RA was associated with improvements in clinical measurements and was negatively associated with smoking in contrast to ACPA that was associated with worseneing of clinical symptoms and associated positively with smoking. Anti-CII levels associated to  HLADRB1*03 and  HLADRB1*01 whereas ACPA showed negative association to HLA-DRB1*03. In a Malaysian RA cohort anti-CII also associated to elevated CRP at the time of diagnosis. Anti-CII seropositive RA represents a distinct phenotype, in many respects representing the converse  to the clinical, genetic and smoking associations described for ACPA. Early determinations of anti-CII in parallel to ACPA predict the inflammatory outcome in RA.
APA, Harvard, Vancouver, ISO, and other styles
3

Dahlström, Örjan. "Focus on Chronic Disease through Different Lenses of Expertise : Towards Implementation of Patient-Focused Decision Support Preventing Disability: The Example of Early Rheumatoid Arthritis." Doctoral thesis, Linköpings universitet, Institutionen för beteendevetenskap och lärande, 2009. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-18112.

Full text
Abstract:
Introduction: Rheumatoid arthritis (RA) is a chronic inflammatory disease. Treatment strategies emphasize early multi-professional interventions to reduce disease activity and to prevent disability, but there is a lack of knowledge on how optimal treatment can be provided to each individual patient. Aim: To elucidate how clinical manifestations of early RA are associated to disease and disability outcomes, to strive for greater potential to establish prognosis in early RA, and to facilitate implementation of decision support through analyses of the decision-making environment in chronic care. Methods: Multivariate statistics and mathematical modelling, as well as field observations and focus group interviews. Results: Decision support: A prognostic tree that predicted patients with a poor prognosis (moderate or high levels of DAS-28) at one year after diagnosis had a performance of 25% sensitivity, 90% specificity and a positive predictive value of 76%. Implementation of a decision support application at a rheumatology unit should include taking into account incentive structures, workflow and awareness, as well as informal communication structures. Prognosis: A considerable part of the variance in disease activity at one year after diagnosis could be explained by disease progression during the first three months after diagnosis. Using different types of knowledge – different expertise – prior to standardized data mining methods was found to be a promising when mining (clinical) data for new patterns that elicit new knowledge. Disease and disability: Women report more fatigue than men in early RA, although the difference is not consistently significant. Fatigue in early RA is closely and rather consistently related to disease activity, pain and activity limitation, as well as to mental health and sleep disturbance. Conclusion: A decision tree was designed to identify patients at risk of poor prognosis at one year after the diagnosis of RA. When constructing prediction rules for good or poor prognosis, including more measures of disease and disability progressions showed promise. Using different types of knowledge – different lenses of expertise – prior to standardized data mining methods was also a promising method when mining (clinical) data for new patterns that elicit new knowledge.
Introduktion: Reumatoid artrit (RA) är en kronisk inflammatorisk sjukdom. Dagens behandlingsstrategi bygger på tidiga multiprofessionella insatser för att reducera sjukdomsaktivitet och minska risken för framtida funktionshinder. Idag finns stora datamängder tillgängliga gällande medicinering och utfall vid RA. Dessa data erbjuder möjligheter att generera ny kunskap som kan användas för att forma beslutsstöd. Syfte: Att undersöka hur olika kliniska manifestationer vid tidig RA samvarierar med funktionshinder och sjukdomsaktivitet, att pröva metoder att ställa prognos vid tidig RA, och att analysera en kontext för beslutsfattande inom vård av kroniskt sjuka. Metod: Multivariat statistik och matematisk modellering, samt observationsstudier och fokusgruppsintervjuer. Resultat: Beslutsstöd: Ett beslutsträd utformades för att bestämma vilka patienter som har dålig prognos (måttlig eller hög DAS-28) ett år efter diagnos. Beslutsträdet hade 25 % sensitivitet, 90 % specificitet och ett positivt prediktivt värde på 76 %. Vid införande av beslutsstöd på en reumatologisk klinik befanns det nödvändigt att hänsyn tas till incitamentsstrukturer, arbetsflöde och samarbetsformer. Informella kommunikationsstrukturer kan också ha stort inflytande på klinisk praxis. Prognos: En betydande del av variansen i sjukdomsaktivitet ett år efter diagnos kan förklaras av sjukdomsprogression första tre månaderna efter diagnos. Att formalisera olika experters erfarenheter före standardiserade ”data mining” metoder är en lovande ansats när man letar efter mönster i (kliniska) databaser. Funktionshinder och sjukdomsaktivitet: Kvinnor rapporterar mer trötthet än män vid tidig RA, men skillnaden är inte konsistent över tid. Trötthet vid tidig RA är nära relaterat till sjukdomsaktivitet, smärta och aktivitets begränsningar, men också till mental hälsa och sömnstörningar. Slutsats: Ett beslutsträd har utformats för att predicera patienter med dålig prognos inom tidig RA. Studier av fler mått på sjukdoms- och funktionshindersprogression behövs vid konstruktion av prediktionsregler för god eller dålig prognos framledes. Att använda sig av kunskap från olika experter – olika experters glasögon – vid sökandet efter mönster i stora datamängder för att generera ny kunskap är en lovande metodik. Implementering av beslutsstöd bör göras under övervägande av incitamentsstrukturer, arbetsflöde och samarbetsformer.
APA, Harvard, Vancouver, ISO, and other styles
4

Hui, Kwun-ho. "The diagnostic and prognostic value of anti-CCP assay in the juvenile idiopathic arthritis (JIA)." Click to view the E-thesis via HKUTO, 2004. http://sunzi.lib.hku.hk/hkuto/record/B31971817.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hui, Kwun-ho, and 許冠浩. "The diagnostic and prognostic value of anti-CCP assay in the juvenile idiopathic arthritis (JIA)." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2004. http://hub.hku.hk/bib/B31971817.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bejarano, Victoria. "Use of novel prognostic tools, outcome measures and therapeutic strategies in early rheumatoid arthritis." Thesis, University of Leeds, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.558797.

Full text
Abstract:
Though the management of rheumatoid arthritis (RA) has recently been revolutionised, the optimal initial therapeutic regimen in the vital early stages is not known and critically the long-term effects of currently proposed regimens are not well documented. Patients with an expected poor prognosis would gain most from early treatment with highly effective but expensive new therapies; this highlights the need for better prognostic tools. Modern outcomes for RA should reflect patient expectations, for example, participation in work. In this thesis, evidence of the long-term effects of 2 initial therapeutic regimens in early RA was sought. Patients treated with an initial combination of methotrexate (MTX), ciclosporin A (CsA) and intraarticular glucocorticoids in early, poor prognosis RA required less biological agents after 7 years, compared with sulfasalazine (SSZ) monotherapy. The toxicity associated with CsA was reversible. Similarly patients that received an initial combination of infliximab plus MTX for early, poor prognosis RA had better disease control at 8 years than those who had initial MTX monotherapy. Dual energy X-ray absorptiometry (DXA) was tested as a prognostic tool in early RA given its reliability and easy availability. DXA measured hand bone loss during the first year of treatment was associated with radiographic progression at 6 years; however this did not perform better than a baseline radiograph. Imminent and actual job loss were proposed as patient reported outcomes in early RA. Patients receiving an initial combination of adalimumab plus MTX in early RA had a larger improvement in work related outcomes compared with MTX monotherapy. In summary initial therapeutic combinations in early RA can offer short and long-term benefits compared with monotherapy when measuring modern patient relevant and traditional outcomes. There is still a need for clinically useful prognostic tools in early disease.
APA, Harvard, Vancouver, ISO, and other styles
7

Nikiforou, E. "Orthopaedic intervention in rheumatoid arthritis : a retrospective analysis of incidence, prognostic markers and costs." Thesis, University College London (University of London), 2013. http://discovery.ucl.ac.uk/1420127/.

Full text
Abstract:
Background: Orthopaedic surgery in Rheumatoid Arthritis (RA) is an established intervention of long-term disease and a surrogate marker of joint destruction. Methods: This thesis examines orthopaedic data from the Early RA Study (1986-1999, 9 centres, n=1465) and the Early RA Network (2002-2012, 23 centres, n=1236) with linkage to national datasets (Hospital Episode Statistics, National Joint Registry and Office of National Statistics). Clinical and laboratory measures and hand and foot radiographs were standardised and performed yearly in both cohorts. Disease modifying, glucocorticosteroid and biologic therapies reflected conventional practice and guidelines of the time frames examined. Recruitment years were grouped into 6 periods, interventions classified into major, intermediate and minor categories. Cost analysis was based on the Norfolk Arthritis Register (1989-date, n>5000). Results: A total of 1602 surgical procedures were performed in 770 patients (29%). Declines in the rates of hand/foot surgery from 1986-2011 (p<0.001) coincided with secular changes in therapy. No secular variation was seen for large joint replacements. Low haemoglobin predicted shorter time to both major and intermediate surgery (p<0.001). There were declines in median length of stay over time for large, intermediate and minor procedures (8,3,1 days respectively). The mean annual direct health cost per RA patient was £3,430 (over 50% representing medications). The COI of RA in England was estimated at £1.46 billion. Conclusions: This study has compiled the largest, longest and most extensively linked RA- related orthopaedic surgery database in the UK. The declines in intermediate-type surgery during recruitment periods where early and intensive treatments were employed, suggests the impact of these treatments. The thesis demonstrates the predictive power of standard clinical measures in the first year of disease on orthopaedic surgery up to 25 years later. It demonstrates the high economic burden of RA and could be used as a basis for future cost- effectiveness and cost-benefit analyses.
APA, Harvard, Vancouver, ISO, and other styles
8

Biernath, Kristof [Verfasser]. "Bedeutung der Matrix-Metalloproteinase-3-Serum-Spiegel für die Prognose bei Patienten mit rheumatoider Arthritis / Kristof Heinrich Walter Gerald Biernath." Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2015. http://d-nb.info/1079525262/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Biernath, Kristof Heinrich Walter Gerald [Verfasser]. "Bedeutung der Matrix-Metalloproteinase-3-Serum-Spiegel für die Prognose bei Patienten mit rheumatoider Arthritis / Kristof Heinrich Walter Gerald Biernath." Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2015. http://d-nb.info/1079525262/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Huscher, Dörte [Verfasser]. "Versorgungsepidemiologie der rheumatoiden Arthritis in der vergangenen Dekade – Prognose, neue Behandlungsziele und aktuelle Kostenentwicklungen : eine Analyse von Daten der Kerndokumentation der Regionalen Kooperativen Rheumazentren in der Deutschen Gesellschaft für Rheumatologie / Dörte Huscher." Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2015. http://d-nb.info/1075757525/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Rheumatoid arthritis Prognosis"

1

Feist, Eugen, and Gerd-R. Burmester. Rheumatoid arthritis—clinical features. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0111.

Full text
Abstract:
Rheumatoid arthritis (RA) presents with variable clinical features, making this most frequent chronic systemic autoimmune disease with characteristic joint involvement a diagnostic and therapeutic challenge. This chapter describes in detail the different clinical, laboratory and imaging findings in patients with RA. In addition to the characteristic arthritic involvement, which can lead to severe joint changes with progressive destruction and loss of function, other systemic disease manifestations as well as an increased risk for cardiovascular events and non-Hodgkin's lymphoma with relevance for patients' prognosis are described. Recent approaches to early diagnosis and stratification of patients by predictive factors for a severe course of disease are discussed. These patient profiles include increased inflammatory markers, the presence of autoantibodies, and erosive changes at the time of diagnosis. The novel classification criteria for RA and the significance of autoantibody status, namely seropositivity for antibodies against citrullinated antigens as highly specific diagnostic markers, are highlighted to further promote early differentiation of RA from other arthritic disease entities.
APA, Harvard, Vancouver, ISO, and other styles
2

1950-, Bellamy Nicholas, ed. Prognosis in the rheumatic diseases. Dordrecht: Kluwer Academic Publishers, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Deighton, Chris. Rheumatoid arthritis—management. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0112.

Full text
Abstract:
Influential guidelines on rheumatoid arthritis (RA) management agree on most key recommendations. Early diagnosis of persistent synovitis, and identification of poor prognostic markers, is essential. Rapid intervention is vital with drugs to suppress inflammation, slow down damaging disease components, and prevent disability. The label of RA covers a broad spectrum of disease severity, and there is controversy on: • whether the same interventions are needed for all patients • whether monotherapy or combination treatment is appropriate • the role of steroids in RA • the appropriate introduction of biological therapies. Treating to specified targets is optimal evidence-based practice, where patients are reviewed regularly for disease activity assessments, and inadequate control rectified. Aiming for remission is the ultimate goal, though for some patients minimal disease activity may be appropriate. Patient education addressing self-management is important, and the multidisciplinary team (MDT: specialist nurses, physiotherapists, occupational therapists, podiatrists, psychologists) needs to be involved from the start to minimize the impact on quality of life of the patient. For established disease, rapid access is important for flares, and to consider whether disease management could be improved. An intermittent overview of established disease is important with access to the MDT, and assessments for comorbidities such as ischaemic heart disease, osteoporosis, and depression, as well as complications of the disease itself such as cervical spine disease, vasculitis, and lung and eye complications. An informed patient needs to be central to all decision making.
APA, Harvard, Vancouver, ISO, and other styles
4

Watts, Richard A., and Eleana Ntatsaki. Miscellaneous vasculitides. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0137.

Full text
Abstract:
The vasculitides are a group of relatively rare conditions with a broad spectrum of clinical presentations that can cause significant morbidity and mortality. Classification of the vasculitic syndromes is done according to the size of the vessels affected and also the presence of anti-neutrophil cytoplasmic antibodies (ANCA). Vasculitides can be either primary or secondary to an underlying systemic disease, malignancy, or infection. This chapter covers the spectrum of the secondary vasculitides; some of the non-ANCA-associated primary vasculitides and miscellaneous types of vasculitic syndromes. Secondary vasculitis can occur in the background of systemic rheumatic diseases such as rheumatoid arthritis, spondyloarthropathies, or other connective tissue diseases. Vasculitis can also present in relation to precipitants such as drugs (propylthiouracil, hydralazine, leucotriene antagonists) or vaccines. Infection (bacterial, mycobacterial, viral, and fungal) has been associated with vasculitis either as a trigger or as a consequence of iatrogenic immunosuppression. Infection-related vasculitis can affect all types and sizes of vessels. Certain forms of vasculitis such as cryoglobulinaemia are closely associated with viral infections and more specifically with HCV infection. There are forms of vasculitis, which appear to be isolated or localized to a single organ, or site (skin, gastrointestinal, genital, and primary central nervous system vasculitis) that may be histologically similar to systemic syndromes, but have a different prognosis. Other conditions that may mimic vasculitis and miscellaneous conditions such as Cogan's syndrome and relapsing polychondritis are also discussed.
APA, Harvard, Vancouver, ISO, and other styles
5

Controlling progression of severe rheumatoid arthritis: New perspectives on prognostic markers and treatment : proceedings of a satellite symposium, Amsterdam, The Netherlands, 19 June 1995. Oxford: Oxford University Press, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Hoyles, Rachel K., and Athol U. Wells. Respiratory system. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0020.

Full text
Abstract:
Pulmonary involvement is common in the connective tissue diseases (CTDs) and is associated with significant morbidity and mortality. Improved management of systemic disease has led to increasing numbers of surviving patients with clinically significant pulmonary disease. Screening for pulmonary complications highlights the frequency of subclinical involvement. In this chapter, the pulmonary manifestations of the more common CTDs are detailed, including rheumatoid arthritis (RA), systemic sclerosis (SSc), systemic lupus erythematosus (SLE), polymyositis/dermatomyositis (PM/DM), Sjögren's syndrome (SS), and, more briefly, ankylosing spondylitis (AS). A broad spectrum of pulmonary disorders are seen in association with the CTDs or the drugs used to treat the underlying disorder, including interstitial lung disease, pulmonary infections, airways disease, pulmonary nodules, pleural disease, chest wall pathology and pulmonary vascular disease; the discussion is stratified by pulmonary complication. In many cases, two or more pulmonary manifestations of CTD coexist or there are other concurrent diseases such as asthma and lung cancer, resulting in potentially confusing mixed imaging and pulmonary function abnormalities. This chapter presents a comprehensive approach to the investigation, screening, prognostic evaluation, and treatment decisions in pulmonary disease associated with the CTDs.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Rheumatoid arthritis Prognosis"

1

Wolfe, F. "Rheumatoid arthritis." In Prognosis in the Rheumatic Diseases, 37–82. Dordrecht: Springer Netherlands, 1991. http://dx.doi.org/10.1007/978-94-011-3896-3_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bhalla, Parinishtha, Anukriti Verma, Bhawna Rathi, Shivani Sharda, and Pallavi Somvanshi. "Exploring Molecular Signatures in Spondyloarthritis: A Step Towards Early Diagnosis." In Proceedings of the Conference BioSangam 2022: Emerging Trends in Biotechnology (BIOSANGAM 2022), 142–55. Dordrecht: Atlantis Press International BV, 2022. http://dx.doi.org/10.2991/978-94-6463-020-6_15.

Full text
Abstract:
AbstractSpondyloarthritis is an acute inflammatory disorder of the musculoskeletal system often accompanied by pain, stiffness, bone and tissue damage. It majorly consists of ankylosing spondylitis, psoriatic arthritis and reactive arthritis. It follows a differential diagnosis pattern for demarcation between the spondyloarthritis subtypes and other arthritic subtypes such as rheumatoid arthritis, juvenile arthritis and osteoarthritis due to the heterogeneity causing gradual chronicity and complications. Presence of definite molecular markers can not only improve diagnosis efficiency but also aid in their prognosis and therapy. This study is an attempt to compose a refined list of such unique and common molecular signatures of the considered subtypes, by employing a reductionist approach amalgamating gene retrieval, protein-protein interaction network, functional, pathway, micro-RNA-gene and transcription factor-gene regulatory network analysis. Gene retrieval and protein-protein interaction network analysis resulted in unique and common interacting genes of arthritis subtypes. Functional annotation and pathway analysis found vital functions and pathways unique and common in arthritis subtypes. Furthermore, miRNA-gene and transcription factor-gene interaction networks retrieved unique and common miRNA’s and transcription factors in arthritis subtypes. Furthermore, the study identified important signatures of arthritis subtypes that can serve as markers assisting in prognosis, early diagnosis and personalized treatment of arthritis patients requiring validation via prospective experimental studies.
APA, Harvard, Vancouver, ISO, and other styles
3

Marshall, W. H., S. Drover, B. A. Larsen, D. Codner, M. D. Copp, J. Gamberg, E. Keystone, D. Gladman, and J. Wade. "Assessing Prognosis in Rheumatoid Arthritis Using Monoclonal Antibodies and Flow Cytometry." In Immunogenetics: Advances and Education, 87–98. Dordrecht: Springer Netherlands, 1997. http://dx.doi.org/10.1007/978-94-011-5486-4_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ansell, B. M. "Juvenile arthritis." In Prognosis in the Rheumatic Diseases, 83–96. Dordrecht: Springer Netherlands, 1991. http://dx.doi.org/10.1007/978-94-011-3896-3_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Gladman, D. D. "Psoriatic arthritis." In Prognosis in the Rheumatic Diseases, 153–66. Dordrecht: Springer Netherlands, 1991. http://dx.doi.org/10.1007/978-94-011-3896-3_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bellamy, N., R. R. Grigor, and R. P. Naden. "Arthritis in pregnancy." In Prognosis in the Rheumatic Diseases, 279–319. Dordrecht: Springer Netherlands, 1991. http://dx.doi.org/10.1007/978-94-011-3896-3_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Schneider, M., M. Lelgemann, H. H. Abholz, M. Blumenroth, C. Flügge, M. Gerken, H. Jäniche, et al. "Diagnose und Prognose der frühen rheumatoiden Arthritis (RA)." In Interdisziplinäre Leitlinie, 5–12. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-23269-5_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Feist, Eugen, and Gerd-R. Burmester. "Rheumatoid arthritis—clinical features." In Oxford Textbook of Rheumatology, 858–66. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0111_update_001.

Full text
Abstract:
Rheumatoid arthritis (RA) presents with variable clinical features, making this most frequent chronic systemic autoimmune disease with characteristic joint involvement a diagnostic and therapeutic challenge. This chapter describes in detail the different clinical, laboratory and imaging findings in patients with RA. In addition to the characteristic arthritic involvement, which can lead to severe joint changes with progressive destruction and loss of function, other systemic disease manifestations as well as an increased risk for cardiovascular events and non-Hodgkin’s lymphoma with relevance for patients’ prognosis are described. Recent approaches to early diagnosis and stratification of patients by predictive factors for a severe course of disease are discussed. These patient profiles include increased inflammatory markers, the presence of autoantibodies, and erosive changes at the time of diagnosis. The novel classification criteria for RA and the significance of autoantibody status, namely seropositivity for antibodies against citrullinated antigens as highly specific diagnostic markers, are highlighted to further promote early differentiation of RA from other arthritic disease entities.
APA, Harvard, Vancouver, ISO, and other styles
9

Coumbe, Ben G. T., Elena Nikiphorou, and Tuulikki Sokka-Isler. "Combination therapy in rheumatoid arthritis." In Oxford Textbook of Rheumatoid Arthritis, 457–62. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198831433.003.0037.

Full text
Abstract:
The therapeutic armamentarium available for treatment of rheumatoid arthritis (RA) has changed significantly over the past 30 years, transforming the therapeutic landscape and prognosis for a substantial proportion of patients with RA. Combination therapies represent an important therapeutic paradigm for management of rheumatoid arthritis. The rationale for combination therapies is clear and demonstrated to bring treatment benefit to patients achieving lower disease activity scores and reduced radiologic progression according to ‘treat-to-target’ principles. A rigorous evidence-based debate is required involving not only parameters related to disease activity scores and radiologic progression, but related to the cost-effectiveness analysis of using many of these newer agents compared to older csDMARDs. This chapter addresses the evidence related to the utilization of combination strategies for the management of RA as compared to monotherapy.
APA, Harvard, Vancouver, ISO, and other styles
10

Gibson, Kathryn A., and Theodore Pincus. "Patient physical function in rheumatoid arthritis." In Oxford Textbook of Rheumatoid Arthritis, 221–50. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198831433.003.0020.

Full text
Abstract:
A patient history is far more prominent in diagnosis and management of rheumatoid arthritis (RA) than in many chronic diseases, such as hypertension and diabetes, in which biomarkers dominate clinical decisions. A patient history traditionally has been termed ‘subjective’, based on narrative descriptions, in contrast to ‘objective’ high-technology laboratory and other measures. Self-report questionnaires provide standard, quantitative, reproducible medical history data, which meet criteria for the ‘scientific method’. Patient self-report scores for physical function distinguish active from control treatment results in RA clinical trials as effectively as laboratory tests, joint counts, or indices which include these measures. Self-report physical function generally is more reproducible than joint counts, and more significant than radiographic scores or laboratory tests in the prognosis of severe RA outcomes of work disability and mortality, providing a prognostic indicator analogous to blood pressure or haemoglobin A1C. Four prominent, feasible self-report questionnaires are the Health Assessment Questionnaire (HAQ), its multidimensional version (MDHAQ), the 36-item Short Form (SF-36), and Patient-Reported Outcomes Measurement Information System (PROMIS). The MDHAQ also includes ‘medical’ information (i.e. self-report joint count, symptom checklist, and medical history). Despite documentation of their scientific value and pragmatic advantages to document relevant information while saving time, patient questionnaires remain regarded primarily as providing ancillary rather than essential information to inform clinical decisions, based in part on perceived barriers concerning feasibility and complexities to interface with electronic medical records. Quantitative assessment of physical function on patient questionnaires prior to every routine rheumatology encounter could improve patient care and outcomes.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Rheumatoid arthritis Prognosis"

1

YAMAUCHI, Morio, Kazuhisa NAKANO, Yoshiya TANAKA, and Keiichi HORIO. "Predicting Disease Activity for Biologic Selection in Rheumatoid Arthritis." In 9th International Conference on Signal, Image Processing and Pattern Recognition (SPPR 2020). AIRCC Publishing Corporation, 2020. http://dx.doi.org/10.5121/csit.2020.101913.

Full text
Abstract:
In this article, we implemented a regression model and conducted experiments for predicting disease activity using data from 1929 rheumatoid arthritis patients to assist in the selection of biologics for rheumatoid arthritis. On modelling, the missing variables in the data were completed by three different methods, mean value, self-organizing map and random value. Experimental results showed that the prediction error of the regression model was large regardless of the missing completion method, making it difficult to predict the prognosis of rheumatoid arthritis patients.
APA, Harvard, Vancouver, ISO, and other styles
2

Kocakaya, Derya, Aysun Aksoy, Yasemin Yalçınkaya, Nevsun Inanç, Emel Eryüksel, and Sait Karakurt. "Cavitary nodules in rheumatoid arthritis patients and their prognosis." In ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.pa4116.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Denis, A., C. Regnier, M. Henket, N. Maes, M. Thys, R. Louis, M. Malaise, and J. Guiot. "Airflow obstruction as a marker of prognosis in rheumatoid arthritis." In ERS International Congress 2022 abstracts. European Respiratory Society, 2022. http://dx.doi.org/10.1183/13993003.congress-2022.2411.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Meissner, Y., M. Schäfer, B. Manger, M. Zänker, W. Ochs, J. Listing, and A. Strangfeld. "THU0142 The prognosis of heart failure in patients with rheumatoid arthritis." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.3979.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Jung, S. Y., J. J. choi, and S. K. lee. "AB1217 Fluorometric imaging for early diagnosis and prognosis of rheumatoid arthritis." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.5339.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Hyldgaard, Charlotte, Anders Løkke, Alma Becic Pedersen, Sinna Pilgaard Ulrichsen, Ole Hilberg, Elisabeth Bendstrup, and Torkell Ellingsen. "Prognosis in rheumatoid arthritis patients with COPD: A nationwide, registry-based study." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.oa1786.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ziade, Nelly, Amani Daher, Bassel Zorkany, Samar Al Emadi, Hussein Halabi, Mohammad Abu Jbara, Lina Kibbi, et al. "THU0108 11. RHEUMATOID ARTHRITIS – PROGNOSIS, PREDICTORS AND OUTCOME CONCORDANCE BETWEEN PHYSICIAN AND PATIENT ASSESSMENT OF DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS USING DISEASE ACTIVITY SCORE." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.6055.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Assefnia, Shahin, Sivanesan Dakshanamurthy, Jaime M. Guidry Auvil, Constanze Hampel, Panos Anastasiadis, Bhaskar Kallakury, Aykut Uren, et al. "Abstract A045: Cadherin-11, a common therapeutic target in poor prognosis malignancies and rheumatoid arthritis." In Abstracts: AACR Special Conference on Advances in Breast Cancer Research: Genetics, Biology, and Clinical Applications - October 3-6, 2013; San Diego, CA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1557-3125.advbc-a045.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Reyes, Felipe, Silvana Saavedra, Karen Vergara, Matias Florenzano, and Veronica Wolff. "Rheumatoid arthritis-related interstitial lung disease (RA-ILD): Clinical, functional features, and variables associated poor initial prognosis in a chilean cohort." In ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.3481.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kato, Go, Koichiro Takahashi, Kohei Nagawasa, Sinya Kimura, and Shinichiro Hayashi. "Honeycomb Dominant- And Ground Glass Opacity/Reticular Shadow Dominant-Interstitial Lung Disease Are Associated With A Good Prognosis In Rheumatoid Arthritis." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a2363.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Rheumatoid arthritis Prognosis' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography